Unknown

Dataset Information

0

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

ABSTRACT: Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.

SUBMITTER: Mateo F 

PROVIDER: S-EPMC5442428 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

Mateo F F   Arenas E J EJ   Aguilar H H   Serra-Musach J J   de Garibay G Ruiz GR   Boni J J   Maicas M M   Du S S   Iorio F F   Herranz-Ors C C   Islam A A   Prado X X   Llorente A A   Petit A A   Vidal A A   Català I I   Soler T T   Venturas G G   Rojo-Sebastian A A   Serra H H   Cuadras D D   Blanco I I   Lozano J J   Canals F F   Sieuwerts A M AM   de Weerd V V   Look M P MP   Puertas S S   García N N   Perkins A S AS   Bonifaci N N   Skowron M M   Gómez-Baldó L L   Hernández V V   Martínez-Aranda A A   Martínez-Iniesta M M   Serrat X X   Cerón J J   Brunet J J   Barretina M P MP   Gil M M   Falo C C   Fernández A A   Morilla I I   Pernas S S   Plà M J MJ   Andreu X X   Seguí M A MA   Ballester R R   Castellà E E   Nellist M M   Morales S S   Valls J J   Velasco A A   Matias-Guiu X X   Figueras A A   Sánchez-Mut J V JV   Sánchez-Céspedes M M   Cordero A A   Gómez-Miragaya J J   Palomero L L   Gómez A A   Gajewski T F TF   Cohen E E W EEW   Jesiotr M M   Bodnar L L   Quintela-Fandino M M   López-Bigas N N   Valdés-Mas R R   Puente X S XS   Viñals F F   Casanovas O O   Graupera M M   Hernández-Losa J J   Ramón Y Cajal S S   García-Alonso L L   Saez-Rodriguez J J   Esteller M M   Sierra A A   Martín-Martín N N   Matheu A A   Carracedo A A   González-Suárez E E   Nanjundan M M   Cortés J J   Lázaro C C   Odero M D MD   Martens J W M JWM   Moreno-Bueno G G   Barcellos-Hoff M H MH   Villanueva A A   Gomis R R RR   Pujana M A MA  

Oncogene 20161219 19

Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and pos  ...[more]

Similar Datasets

Unknown Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional network.
| S-EPMC3097468 | biostudies-literature
Unknown mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
| S-EPMC4898154 | biostudies-literature
Unknown E2F1 inhibition mediates cell death of metastatic melanoma.
| S-EPMC5943238 | biostudies-literature
Unknown mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging.
| S-EPMC2939833 | biostudies-literature
Unknown Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties.
| S-EPMC8164635 | biostudies-literature
Unknown FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells.
| S-EPMC4253450 | biostudies-literature
Unknown Genome Architecture Mediates Transcriptional Control of Human Myogenic Reprogramming.
| S-EPMC6137960 | biostudies-literature
Unknown Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
| S-EPMC3384429 | biostudies-literature
Unknown AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.
| S-EPMC9935518 | biostudies-literature
Unknown AXL mediates resistance to PI3K? inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
| S-EPMC4398915 | biostudies-literature